RxDoctor Payments Data

Kristen Rainear, DO

Cardiovascular Disease · Vineland, NJNPI 1689662165

Payments from drug & device makers

$83,020in general payments, 2019–2025

Across 224 payments — averaging $370.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$70K
  • Boston Scientific$11K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$592
  • Impulse Dynamics (USA) Inc.$209
  • Medtronic$207
  • Novartis$196
  • plus $984 from 15 others

What the payments were for

  • Speaking & faculty fees$77,35093%
  • Travel & lodging$1,1631%
  • Food & beverage$4,5065%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,020 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$455,353
Medicare patients
1,131
Services billed
6,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban462$608,559
EntrestoSacubitril/Valsartan358$508,750
EliquisApixaban392$430,780
Repatha SureclickEvolocumab227$240,948
JardianceEmpagliflozin96$123,180
FarxigaDapagliflozin Propanediol78$101,076
Repatha SyringeEvolocumab74$79,926
InpefaSotagliflozin45$53,322
BrilintaTicagrelor17$21,513
Praluent PenAlirocumab26$17,357
Metoprolol Succinate973$17,036
KerendiaFinerenone11$13,715
Atorvastatin Calcium877$13,324
Rosuvastatin Calcium452$12,893
Ezetimibe190$8,573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$69,799$608,559462 claims
NovartisEntresto$196$508,750358 claims
PfizerEliquis$152$430,780392 claims
Boehringer IngelheimJardiance$14$123,18096 claims
AstraZenecaFarxiga, Brilinta$15$122,58895 claims
Lexicon Pharmaceuticals, Inc.Inpefa$104$53,32245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Vineland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →